Radius Pharmaceuticals Announces Victory in Patent Infringement Case Against Orbicular Pharmaceutical Technologies for Osteoporosis Treatment TYMLOS(R)
RBGPF
-13.5000
The Fort Worth Press - Radius Pharmaceuticals Announces Victory in Patent Infringement Case Against Orbicular Pharmaceutical Technologies for Osteoporosis Treatment TYMLOS(R)
USD
-
AED 3.672501
AFN 63.495489
ALL 83.192586
AMD 375.730804
ANG 1.790083
AOA 916.999989
ARS 1383.990646
AUD 1.452226
AWG 1.8
AZN 1.697632
BAM 1.693993
BBD 2.007535
BDT 122.298731
BGN 1.709309
BHD 0.376597
BIF 2960.807241
BMD 1
BND 1.28353
BOB 6.91265
BRL 5.2553
BSD 0.996752
BTN 94.473171
BWP 13.741284
BYN 2.966957
BYR 19600
BZD 2.004591
CAD 1.387005
CDF 2282.496424
CHF 0.795017
CLF 0.023433
CLP 925.259734
CNY 6.91185
CNH 6.92068
COP 3662.985579
CRC 462.864319
CUC 1
CUP 26.5
CVE 95.504742
CZK 21.2958
DJF 177.489065
DKK 6.492703
DOP 59.330475
DZD 133.010264
EGP 52.781589
ERN 15
ETB 154.083756
EUR 0.866103
FJD 2.257405
FKP 0.752712
GBP 0.750441
GEL 2.679862
GGP 0.752712
GHS 10.921138
GIP 0.752712
GMD 73.500634
GNF 8739.335672
GTQ 7.62808
GYD 208.64406
HKD 7.82615
HNL 26.46399
HRK 6.5452
HTG 130.656966
HUF 338.089034
IDR 16990.8
ILS 3.13762
IMP 0.752712
INR 94.850202
IQD 1305.703521
IRR 1313250.000216
ISK 124.760128
JEP 0.752712
JMD 156.892296
JOD 0.708974
JPY 160.287037
KES 129.470356
KGS 87.450219
KHR 3992.031527
KMF 428.0001
KPW 900.00296
KRW 1508.000246
KWD 0.30791
KYD 0.830627
KZT 481.867394
LAK 21678.576069
LBP 89256.247023
LKR 313.975142
LRD 182.893768
LSL 17.115586
LTL 2.95274
LVL 0.60489
LYD 6.362652
MAD 9.315751
MDL 17.507254
MGA 4153.999394
MKD 53.388766
MMK 2098.832611
MNT 3571.142668
MOP 8.042181
MRU 39.797324
MUR 46.77056
MVR 15.449908
MWK 1728.292408
MXN 18.140005
MYR 3.923953
MZN 63.950136
NAD 17.115586
NGN 1383.460041
NIO 36.680958
NOK 9.702861
NPR 151.156728
NZD 1.737333
OMR 0.38408
PAB 0.996752
PEN 3.472089
PGK 4.307306
PHP 60.549842
PKR 278.184401
PLN 3.72091
PYG 6516.824737
QAR 3.634057
RON 4.427298
RSD 101.684639
RUB 81.511073
RWF 1455.545451
SAR 3.752751
SBD 8.042037
SCR 15.03876
SDG 601.000048
SEK 9.47367
SGD 1.292698
SHP 0.750259
SLE 24.55019
SLL 20969.510825
SOS 569.659175
SRD 37.601032
STD 20697.981008
STN 21.220389
SVC 8.721147
SYP 110.527654
SZL 17.114027
THB 32.495002
TJS 9.523624
TMT 3.5
TND 2.938634
TOP 2.40776
TRY 44.440189
TTD 6.772336
TWD 32.044406
TZS 2571.564679
UAH 43.689489
UGX 3713.134988
UYU 40.344723
UZS 12155.385215
VES 467.928355
VND 26337.5
VUV 119.385423
WST 2.775484
XAF 568.149495
XAG 0.014291
XAU 0.000222
XCD 2.70255
XCG 1.796371
XDR 0.706596
XOF 568.149495
XPF 103.295656
YER 238.601083
ZAR 17.089659
ZMK 9001.202399
ZMW 18.763154
ZWL 321.999592
- Rheinmetall addresses row over CEO's Ukraine 'housewives' comment
- Hungary's anxious rural voters will decide Orban's fate
- Defiant Pochettino ready for 'even greater' Portugal test
- Rohit and Rickelton power Mumbai to IPL win over Kolkata
- Pakistan says growing support for its Mideast war talks plan
- Russian tanker nears Cuba, defying US oil blockade
- 'Project Hail Mary' tops N. America box office for second week
- Forty new migratory species win international protection: UN body
- Freed whale gets stranded again off German coast
- Freed whale gets stranded again on German coast
Radius Pharmaceuticals Announces Victory in Patent Infringement Case Against Orbicular Pharmaceutical Technologies for Osteoporosis Treatment TYMLOS(R)
BOSTON, MA / ACCESS Newswire / July 31, 2025 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced today that the U.S. District Court for the District of Massachusetts has ruled in favor of Radius and co-plaintiff Ipsen Pharma S.A.S. ("Ipsen") in a patent infringement suit against Orbicular Pharmaceutical Technologies Private Ltd. ("Orbicular") for their proposed generic for TYMLOS® (abaloparatide) for osteoporosis. Radius and Ipsen prevailed, and the court upheld the validity of all five TYMLOS® patents asserted, in which the latest to expire will remain in effect through April 30, 2038.
The suit was brought by Radius and Ipsen in September 2022 alleging patent infringement by Orbicular in their attempt to seek FDA approval to market a generic abaloparatide product. Radius asserted that Orbicular's proposed generic product would infringe five patents held by Radius.
The favorable ruling reinforces the strength of the TYMLOS® patent portfolio and represents an important win for Radius.
About Radius:
Radius is a global biopharmaceutical company dedicated to transforming the future for underserved, global patient populations in bone health and related areas. Radius' lead product, TYMLOS® (abaloparatide) injection, a parathyroid hormone related peptide, is approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women and men with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture) or patients who have failed or are intolerant to other available osteoporosis therapy. Abaloparatide is supplied as a single-patient multi-use prefilled pen designed to subcutaneously administer 80 micrograms per dose over a 30-day period. For additional information, please visit www.TYMLOS.com.
Contact:
Al Medwar: Senior Vice President, Business and Corporate Development, Radius
Email: [email protected]
SOURCE: Radius Health
View the original press release on ACCESS Newswire
G.George--TFWP
